<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ESTRONE</span><br/>(ess'trone)<br/><span class="topboxtradename">Kestrone 5<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">estrogen</span><br/><b>Prototype: </b>Estradiol<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>First sex hormone isolated in pure form; present in urine of pregnant mares along with other estrogens.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Binds to intracellular receptors that stimulate DNA and RNA to synthesize proteins responsible for effects of estrogen.</p>
<h1><a name="uses">Uses</a></h1>
<p>Atrophic vaginitis, kraurosis vulvae, and abnormal bleeding (hormonal imbalance); also female hypogonadism, primary ovarian
         failure, vasomotor symptoms associated with menopause, and as palliative therapy of prostatic carcinoma.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Breast cancer; known or suspected pregnancy (category X), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypertension; gallbladder disease; diabetes mellitus; heart failure; liver or kidney dysfunction; history of thromboembolic
         disease.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Menopause</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 0.10.5 mg 23 times/wk<br/><br/><span class="indicationtitle">Female Hypogonadism, Primary Ovarian Failure</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 0.11 mg/wk in single or divided doses<br/><br/><span class="indicationtitle">Inoperable Prostatic Cancer Palliation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 24 mg/d 23 times/wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Shake vial and syringe well to suspend medication before withdrawing and injecting medication.</li>
<li>Give deep into a large muscle.</li>
<li>Store at 15°30° C (59°86° F); protect from light and do not freeze.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness, depression, <span class="speceff-common">libido changes.</span> <span class="typehead">CV:</span> <span class="speceff-life">Thromboembolic disorders</span>, hypertension. <span class="typehead">GI:</span> <span class="speceff-common">Nausea,</span> vomiting, diarrhea, bloating, cholestatic jaundice. <span class="typehead">Urogenital:</span> Mastodynia, spotting, changes in menstrual flow, dysmenorrhea, amenorrhea. <span class="typehead">Metabolic:</span> Reduced carbohydrate tolerance, fluid retention. <span class="typehead">Other:</span> Leg cramps, intolerance to contact lenses. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span> <b>Carbamazepine,</b> <b>phenytoin,</b> <b>rifampin</b> decrease estrogen levels because they increase its metabolism; may enhance steroid effects of <span class="classification">corticosteroids</span>; may decrease anticoagulant effects of <span class="classification">oral anticoagulants</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Absorption occurs over several days. <span class="typehead">Metabolism:</span> Converts to estradiol in GI mucosa. <span class="typehead">Half-Life:</span> 418.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>See nursing implications under estradiol.</li>
<li>Monitor for and report breakthrough vaginal bleeding.</li>
<li>Assess for relief of menopausal symptoms.</li>
<li>Lab tests: Monitor serum phosphatase levels with prostate cancer.</li>
<li>Monitor patients with conditions that may be influenced by fluid retention carefully (e.g., migraine, cardiac or kidney dysfunction,
            asthma, epilepsy, hypertension). Check BP on a regular basis.
         </li>
<li> 							Note: Spotting or breakthrough bleeding occurring when other drugs and estrone are taken concurrently indicates reduced availability
            of the estrogen. 						
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Review package insert to assure understanding of estrogen therapy.</li>
<li>Determine weight under standard conditions 1 or 2 times/wk and report sudden weight gain or other signs of fluid retention.</li>
<li>Notify physician of positive Homan's sign (calf pain upon flexing foot) and the following symptoms of thromboembolic disorders
            immediately: Tenderness, swelling, and redness in extremity; sudden, severe headache or chest pain; slurring of speech; change
            in vision; sudden shortness of breath.
         </li>
<li>Report symptoms of vaginal candidiasis (thick, white, curd-like secretions and inflamed, congested introitus) to permit appropriate
            treatment.
         </li>
<li>Notify physician of severe abdominal pain and tenderness or abdominal mass.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>